Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MMR vaccine
MMR, Varicella vacc · 2 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| MeMuRu-OKA (study vac) | BIOLOGICAL | - |
| MMR, Varicella vacc (control) | BIOLOGICAL | - |
| MeMuRu-OKA (study vacc) | BIOLOGICAL | - |
Inclusion Criteria: * Children must be healthy to participate Exclusion Criteria: * immunosuppressive (including HIV) conditions, allergic diseases, neurological disorders, known anaphylactic reaction to MMR vaccine, and fever (axillary temperature ³ 37.5°C at the time of vaccination) are excludi...
MMR, Varicella vacc is an investigational combination vaccine being studied for the prevention of mumps and varicella, as well as measles and rubella. It is in Phase 2 clinical development for use in infectious disease prevention.
MMR, Varicella vacc is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The vaccine is currently in Phase 2 clinical trials.
MMR, Varicella vacc is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. Two Phase 2 trials have been completed to evaluate its immunogenicity and safety.
MMR, Varicella vacc has been studied in two completed Phase 2 clinical trials: NCT00352898 and NCT00353288. Both trials compared the combination vaccine to Priorix given with Varilrix in healthy children aged 15 months and older, across countries including Canada, Italy, France, and Germany.
MMR, Varicella vacc is also known as the MMR vaccine, but it is a combination vaccine that includes varicella in addition to measles, mumps, and rubella components. It is being developed to provide protection against all four diseases in a single shot.